Related Experiment Video
Updated: Jul 19, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Immunomodulation in myelodysplastic syndromes
1Cleveland Clinic Lerner College of Medicine, Department of Hematologic Malignancies and Blood Disorders, Taussig Cancer Center, Cleveland Clinic Foundation, Desk R35, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA. sekerem@ccf.org
Abstract:
The myelodysplastic syndromes (MDS) - bone-marrow stem-cell malignancies that share pathogenetic overlap with acute myeloid leukemia - are characterized by peripheral-blood cytopenias and, in more advanced subtypes, varied degrees of maturation arrest. Premature apoptosis of bone-marrow cellular elements contributes to ineffective hematopoiesis, which is exacerbated by stromal production of inflammatory cytokines. Abrogation of the effects of these cytokines represents an area of active clinical research, particularly in the treatment of low-risk MDS. Agents such as thalidomide, lenalidomide, and infliximab have shown promising efficacy and tolerability in clinical trials, and may represent a springboard for future treatment combinations.
Related Concept Videos
Regulation of Hematopoietic Stem Cells
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Differentiation of Common Myeloid Progenitor Cells
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Mesenchymal Stem Cells
